Semaglutide Side Effects: What the Research Literature Reports

Adverse Event Profile from the Trial Program

Semaglutide's adverse event profile across the STEP, SUSTAIN, and SELECT programs is well-characterized in large randomized populations. Gastrointestinal events are the predominant category; serious adverse events are less common but documented.

All adverse event data cited here are from placebo-controlled randomized trials. The comparisons are semaglutide versus placebo in the same trial population — not versus other drug classes.

Gastrointestinal Adverse Events

Gastrointestinal adverse events — nausea, vomiting, diarrhea, constipation — were reported by up to 74% of semaglutide-treated participants across STEP trials.^[12] In STEP 1, approximately 44% reported nausea, 24% diarrhea, 24% vomiting, and 24% constipation in the semaglutide arm versus approximately 16%, 11%, 6%, and 11% respectively with placebo.^[1]

Severity: most events were mild to moderate. The incidence was highest during dose escalation (weeks 1–20 in the STEP titration schedule) and declined as participants reached and maintained the 2.4 mg maintenance dose.^[12] Discontinuation due to adverse events: 7.0% of semaglutide participants versus 3.1% with placebo in STEP 1.^[1] The discontinuation gap is predominantly GI-driven.

Timing of Semaglutide Side Effects

In clinical trials, GI side effects were most frequent during the dose-escalation phase (weeks 1–20 in the STEP weight management titration).^[12] The 16-week escalation schedule — 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg at 4-week intervals — was specifically designed to allow GI tolerance to develop before reaching maintenance dose. Weekly injections during the escalation period are associated with varying tolerability as each dose step introduces a new peak exposure level.

After week 20 (maintenance dose reached), event rates in STEP 1 data fell substantially, with most participants no longer reporting active GI symptoms. The trial data suggest time-dependent GI adaptation at each dose level.

Managing Common Semaglutide Side Effects

Nausea, vomiting, diarrhea, and constipation were reported by 40–60% of trial participants during titration; slow dose escalation, smaller meals, and adequate hydration are the management strategies described in STEP trial protocols and the FDA label.^[12]

The STEP titration protocol's slow 16-week escalation schedule represents the primary GI-mitigation strategy validated in large trials.^[1] Specific trial-protocol guidance for participants experiencing GI symptoms included splitting meals, avoiding high-fat and high-calorie food items at the time of dose escalation, and maintaining adequate fluid intake. These are trial-protocol descriptions, not clinical management recommendations.

Serious Adverse Events in Semaglutide Trials

Acute pancreatitis was a serious adverse event in trial populations. Pancreatitis was observed in 0.2% of semaglutide-treated participants versus less than 0.1% with placebo in STEP trial data.^[12]

Diabetic retinopathy complications were significantly more common with semaglutide than placebo in SUSTAIN-6: 3.0% versus 1.8% (HR 1.76; p=0.02).^[13] Researchers attributed this to the early-worsening phenomenon associated with rapid HbA1c improvement in subjects with pre-existing retinopathy — a pattern previously documented with rapid insulin-mediated glycemic correction, not a direct drug toxicity.

What Are the Risks and Downsides of Semaglutide?

The most common risks documented in trials are gastrointestinal — nausea, vomiting, diarrhea, constipation — affecting 40–74% of treated participants during dose escalation, mostly at mild-to-moderate severity.^[12] These are the primary reason for the 7% treatment discontinuation rate in STEP 1.

Serious but less common documented risks include pancreatitis (0.2% vs <0.1% with placebo in STEP trials), gallbladder disease (cholelithiasis and cholecystitis were more common with semaglutide in pooled STEP data), and acute kidney injury (reported in some participants with severe dehydration secondary to vomiting/diarrhea).^[12][14]

Lean mass loss is a documented finding. The DXA substudy of STEP 1 showed approximately 10% absolute lean body mass reduction alongside the fat loss.^[11] The clinical implications of this lean-mass decline — particularly for older adults at risk for sarcopenia — are an active area of investigation and have not been resolved in the published literature.

Long-term safety data exist up to approximately 3.4 years (SELECT trial follow-up).^[5] 5–10 year outcomes data are not yet available.

Populations Excluded from Semaglutide Research Trials

Standard exclusion criteria applied consistently across STEP and SUSTAIN trials:^[14]

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia type 2 (MEN-2) syndrome
• History of acute pancreatitis
• Pregnancy

These populations were not studied. The thyroid and MEN-2 exclusions reflect the rodent C-cell tumor signal. The pancreatitis exclusion reflects the acute pancreatitis adverse event signal and the GLP-1 receptor expression on pancreatic acinar cells.

Additionally, individuals with end-stage renal disease (eGFR <15 mL/min/1.73 m²) were excluded from most trials. FLOW enrolled patients with CKD (eGFR 50–75 mL/min/1.73 m² at entry), demonstrating safety and benefit in that range.^[19]

Semaglutide and Hair Loss: Trial Data

Alopecia was reported by approximately 3% of semaglutide-treated subjects versus approximately 1% with placebo in STEP program trials.^[12] In subjects achieving greater than 20% body weight loss, alopecia was reported at higher rates: 5.3% versus 2.5%.^[24]

Researchers characterize the pattern as telogen effluvium — a temporary, reversible form of diffuse hair shedding — hypothesized to be secondary to physiologic stress from rapid caloric restriction and weight loss rather than a direct pharmacologic drug effect.^[24] Hair follicle integrity is maintained; the mechanism is nutritional and physiologic stress-induced entry of follicles into resting phase, not drug-induced follicular damage. The pattern is reversible in most cases documented in the literature.